Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989022 | 0.93 | PIK3R1 (0.35) | PIK3R1PIK3CAMTOR | |
| SCHEMBL2478969 | 0.78 | ALDH1A1 (0.46) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL19175734 | 0.70 | ALDH1A1 (0.40) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL2474178 | 0.69 | POLB (0.60) | SMN1; SMN2KMT2AALDH1A1RECQLGAA | |
| SCHEMBL2472999 | 0.69 | ALDH1A1 (0.39) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL20457039 | 0.69 | ALDH1A1 (0.39) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL2475981 | 0.67 | GAA (0.32) | GAA | |
| SCHEMBL19175466 | 0.66 | ALDH1A1 (0.40) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL7186156 | 0.65 | ALDH1A1 (0.39) | PIK3R1PIK3CAMTORSMN1; SMN2KMT2A | |
| SCHEMBL20063060 | 0.65 | POLB (0.44) | PIK3R1PIK3CAMTORSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | CA3, CA7, KAT5 | PIK3R1 4740/4885PIK3CA 4267/4885MTOR 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.